Primmune Therapeutics to Present Interim Clinical Data from Phase 1 Study Evaluating PRTX007 at the 2022 American Association for Cancer Research (AACR) Annual Meeting
SAN DIEGO--(BUSINESS WIRE)-- Primmune Therapeutics, a biotech company harnessing the power of the innate immune system to treat solid tumors in the advanced cancer setting and for clearing human papilloma virus-driven pre-cancerous cervical lesions, today announced that they will present interim Phase 1 clinical data for PRTX007, a novel, orally administered, small molecule toll-like receptor 7 (TLR7) specific agonist, at the 2022 American Association for Cancer Research (AACR) Annual Meeting. The AACR annual meeting will be held in New Orleans from April 8-13. An e-poster will be made available online Friday, April 8 at 1 p.m. ET.
Title: PRTX007, an Optimized TLR7 Agonist for Systemic Immunotherapy of Cancers: Interim Analysis of Phase I Study in Healthy Volunteers
Presenting Author: Curtis Scribner, M.D.
Abstract Number: 8165
Session Title: Phase I Clinical Trials 2
Session Date and Time: Tuesday, April 12, 9 a.m. CT to 12:30 p.m. CT
Location: New Orleans Convention Center, Exhibit Halls D-H, Poster Section 33
PRTX007 is Primmune’s lead clinical development candidate that is designed to provide well tolerated, controlled, long-term stimulation of the innate immune response while also potentiating long-term effective innate and adaptive immune responses. PRTX007 uniquely activates plasmacytoid dendritic cells (pDCs), leading to a systemic immune poly-IFN response without stimulating production of NF-κB driven proinflammatory factors like IL-6, TNFα or IL-1β. This is functionally equivalent to administering a cocktail of all Type I/III IFN while avoiding the associated side effects and adverse events. PRTX007 is being rapidly advanced towards clinical trials for solid tumors in the advanced cancer setting and for clearing human papilloma virus-driven pre-cancerous cervical lesions.
About Primmune Therapeutics
Primmune Therapeutics is a clinical-stage biotech harnessing the power of the innate immune system by developing small molecule, orally administered toll-like receptor 7 (TLR7) agonists for the treatment of solid tumors in the advanced cancer setting as well as clearance of human papilloma virus-driven pre-cancerous cervical lesions. For more information, please visit https://www.primmunerx.com/.
Source: Primmune Therapeutics